WILFACTIN

is indicated for the treatment and prevention of bleeding and in surgical situations in patients with Willebrand's disease (MW) when treatment alone with desmopressin (DDAVP) is ineffective or contraindicated.

WILFACTIN can be used in all age groups.

WILFACTIN should not be used in the treatment of Hemophilia A.

In the treatment of hemorrhagic episodes, it is recommended that, as a first intention, FVIII be co-administered with the low-FVIII von Willebrand factor in a separate syringe.

Hypersensitivity As with any

Intravenous administered plasma protein, hypersensitivity reactions are possible.

Patients should be closely monitored throughout the duration of the injection to detect any symptoms.

Patients should be informed of early signs of hypersensitivity reactions such as pruritus, urticaria, chest tightness, wheezing, hypotension of the arterial and anaphylactic reaction.

If these symptoms occur, treatment should be interrupted immediately.

In the event of anaphylactic shock, the standard medical treatment should be introduced.Communicable agents The usual measures of prevention of the risk of infectious agents by drugs prepared from blood or from human plasma.

In case of these symptoms, the treatment should be interrupted.

In case of absorbosis, the laboratory virus may be absorbs of the laboratory.

Pharmacotherapeutic group

Antihemorrhagic: blood coagulation factor, Human Willebrand Factor, ATC Code: B02BD10.

WILFACTIN mechanism acts as the endogenous von Willebrand factor.

The von

Willebrand factor is used to correct the hemostasis disorders observed in patients with von Willebrand factor deficiency (Willebrand disease).

• it restores platelet adhesion to the vascular subendothelium at the level of the lesion (the von Willebrand factor being the property of binding both to the vascular subendothelium and to the platelet membrane) which ensures the so-called primary hemostase, as evidenced by the frequently observed shortening of bleeding time.

This effect appears immediately and is known to be largely dependent on the degree of multimerization of the active principle;

• it has delayed action in the associated factor VIII deficits.

After intravenous administration, it attaches itself to the endogenous factor VIII: this is the result of the injection of the initial injection of the initial injection of the initial injection of the initial injection of the initial injection of the initial injection of the initial injection of the initial injection of the initial injection of the initial injection of the initial.

The following adverse reactions may occur during treatment with WILFACTIN: Allergic and anaphylactic reactions (including shock in rare cases), thromboembolic events (mainly in patients with risk factors), formation of VWF inhibitors and administration site reactions Tabulated list of adverse reactions The table below summarizes the adverse reactions observed in 6 clinical trials and a non-intervention post-marketing study, as well as from other post-marketing sources.

In the studies, 226 patients were exposed to WILFACTIN for a total of 16,640 exposure site.

Adverse reactions were classified as

MedDRA (organ system classes), the undesirable terms are not known and the frequency is not known.

The frequency of adverse reactions is not known.